Clinical Trial: ALKS 4230-003

Trial Status: Open
Disease Type: Solid Tumors All
Trial ID ALKS 4230-003

Clinical and Immunologic Activity of Nemvaleukin Alfa With a Less Frequent IV Dosing Schedule as Monotherapy and in Combination with Pembrolizumab and Impact on Tumor Microenvironment in Solid Tumor Patients (ARTISTRY-3)


Fairfax Office

Learn More About This Trial

Other Relevant Trials
Trial ID 516-014
Sponsor ID Mirati

A Multicenter, Open-Label, Extension Study of the Safety and Tolerability of Sitravatinib Alone or in Combination with Other Anticancer Therapies in Patients with Advanced or Metastatic Solid Malignancies

Trial ID JBI-802-101
Sponsor ID Jubilant Therapeutics

A First-in-Human, Open-Label, Dose Escalation and Expansion Study of Orally Administered JBI-802 in Patients with Advanced Solid Tumors